How Close Are We to Using Stem Cells in Routine Cardiac Therapy?

Canadian Journal of Cardiology

Volumn 30, Issue 11, 2014, Pages 1265-1269

  Menasché, Philippe ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Sorbonne University in Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC STEM CELL; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); HEART FUNCTION; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; NONHUMAN; PARACRINE SIGNALING; PLURIPOTENT STEM CELL; QUALITY CONTROL; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE ENGINEERING; CARDIOLOGY; HEART DISEASES; MEDICAL RESEARCH; PROCEDURES;

BIOMEDICAL RESEARCH; CARDIOLOGY; HEART DISEASES; HUMANS; STEM CELL TRANSPLANTATION;

EID: 84908469197     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.03.044     Document Type: Editorial

References (31)

1. Delewi R., Hirsch A., Tijssen J.G., et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J 2014, 35:989-998.
2. Fisher S.A., Dorée C., Brunskill S.J., Mathur A., Martin-Rendon E. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One 2013, 8:e64669.
3. Kandala J., Upadhyay G.A., Pokushalov E., et al. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 2013, 112:217-225.
4. Malliaras K., Zhang Y., Seinfeld J., et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol Med 2013, 5:191-209.
5. Garbern J.C., Lee R.T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013, 12:689-698.
6. den Haan M.C., Grauss R.W., Smits A.M., et al. Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. JCell Mol Med 2012, 16:1508-1521.
7. Wendel JS, Ye L, Zhang P, Tranquillo RT, Zhang JJ. Functional consequences of a tissue-engineered myocardial patch for cardiac repair in a rat infarct model. Tissue Eng Part A 2014;doi:10.1089/ten.TEA.2013.0312.
8. Nguyen B.K., Maltais S., Perrault L.P., et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. JCardiovasc Transl Res 2010, 3:547-558.
9. Timmers L., Lim S.K., Hoefer I.E., et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011, 6:206-214.
10. Fidelis-de-Oliveira P., Werneck-de-Castro J.P., Pinho-Ribeiro V., et al. Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes invitro and improve cardiac function in infarcted rat hearts. Cell Transplant 2012, 21:1011-1021.
11. Mirotsou M., Jayawardena T.M., Schmeckpeper J., Gnecchi M., Dzau V.J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. JMol Cell Cardiol 2011, 50:280-289.
12. Stastna M., Chimenti I., Marbán E., Van Eyk J.E. Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics 2010, 10:245-253.
13. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012, 1820:940-948.
14. Lakhal S., Wood M.J. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic invivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. Bioessays 2011, 33:737-741.
15. Lai R.C., Arslan F., Lee M.M., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010, 4:214-222.
16. Chen L., Wang Y., Pan Y., et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun 2013, 431:566-571.
17. Jay S.M., Lee R.T. Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res 2013, 113:933-943.
18. Bartunek J., Behfar A., Dolatabadi D., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. JAm Coll Cardiol 2013, 61:2329-2338.
19. Malliaras K., Makkar R.R., Smith R.R., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). JAm Coll Cardiol 2014, 63:110-122.
20. Menasché P, Vanneaux V, Fabreguettes JR, et al: Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience [e-pub ahead of print]. Eur Heart J , accessed August 19, 2014. http://dx.doi.org/10.1093/eurheartj/ehu192.
21. Hafner A., Lovrić J., Lakoš G.P., Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine 2014, 9:1005-1023.
22. Brunskill S.J., Hyde C.J., Doree C.J., Watt S.M., Martin-Rendon E. Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail 2009, 11:887-896.
23. Behfar A., Latere J.P., Bartunek J., et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv 2013, 6:710-718.
24. Medicetty S., Wiktor D., Lehman N., et al. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant 2012, 21:1109-1120.
25. Mohsin S., Siddiqi S., Collins B., Sussman M.A. Empowering adult stem cells for myocardial regeneration. Circ Res 2011, 109:1415-1428.
26. Nelson D.M., Ma Z., Fujimoto K.L., Hashizume R., Wagner W.R. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges. Acta Biomater 2011, 7:1-15.
27. Roh J.D., Sawh-Martinez R., Brennan M.P., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A 2010, 107:4669-4674.
28. Sukegawa A., Iwasaki N., Kasahara Y., et al. Repair of rabbit osteochondral defects by an acellular technique with an ultrapurified alginate gel containing stromal cell-derived factor-1. Tissue Eng Part A 2012, 18:934-945.
29. Pashuck E.T., Stevens M.M. Designing regenerative biomaterial therapies for the clinic. Sci Transl Med 2012, 4:160sr4.
30. Toeg H.D., Tiwari-Pandey R., Seymour R., et al. Injectable small intestine submucosal extracellular matrix in an acute myocardial infarction model. Ann Thorac Surg 2013, 96:1686-1694.
31. Fagerholm P., Lagali N.S., Merrett K., et al. Abiosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study. Sci Transl Med 2010, 2:46ra61.